Analyzing IceCure Medical (NASDAQ:ICCM) & Straumann (OTCMKTS:SAUHY)

Straumann (OTCMKTS:SAUHY) and IceCure Medical (NASDAQ:ICCM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Straumann and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Straumann	N/A	N/A	N/A
IceCure Medical	-441.60%	-211.73%	-119.13%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Straumann and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Straumann	2	2	3	0	2.14
IceCure Medical	1	1	3	0	2.40

IceCure Medical has a consensus price target of $62.70, indicating a potential upside of 1,891.74%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Straumann.

Risk and Volatility

Straumann has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares Straumann and IceCure Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Straumann	$3.14 billion	6.50	$429.59 million	N/A	N/A
IceCure Medical	$3.38 million	3.19	-$15.06 million	($7.21)	-0.44

Straumann has higher revenue and earnings than IceCure Medical.

Summary

Straumann beats IceCure Medical on 7 of the 11 factors compared between the two stocks.

About Straumann

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implants and components made from titanium, titanium alloy, and ceramics; prosthetic elements made od ceramics, metal or polymer; and clear aligners. In addition, it offers resins for 3D printing and thermoplastics for clear aligner production; and biomaterials for tissue generation. Further, it provides digital equipment comprising scanners, milling machines and 3D printers. Further, it offers training and education services. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.